Clariane Future Growth

Future criteria checks 3/6

Clariane is forecast to grow earnings and revenue by 96.1% and 5.4% per annum respectively. EPS is expected to grow by 83.1% per annum. Return on equity is forecast to be 1.3% in 3 years.

Key information

96.1%

Earnings growth rate

83.1%

EPS growth rate

Healthcare earnings growth	23.2%
Revenue growth rate	5.4%
Future return on equity	1.3%
Analyst coverage	Low
Last updated	26 Apr 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

ENXTPA:CLARI - Analysts future estimates and past financials data (EUR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	5,887	24	733	792	2
12/31/2025	5,579	58	549	801	4
12/31/2024	5,293	-22	745	788	3
12/31/2023	4,996	-92	320	804	N/A
9/30/2023	4,865	-32	244	799	N/A
6/30/2023	4,735	28	168	794	N/A
3/31/2023	4,587	32	204	828	N/A
12/31/2022	4,438	36	239	862	N/A
6/30/2022	4,288	85	348	900	N/A
3/31/2022	4,212	92	330	870	N/A
12/31/2021	4,137	100	311	840	N/A
9/30/2021	4,047	76	279	818	N/A
6/30/2021	3,941	60	243	785	N/A
3/31/2021	3,857	50	259	790	N/A
12/31/2020	3,773	39	275	795	N/A
9/30/2020	3,728	57	310	765	N/A
6/30/2020	3,683	74	346	734	N/A
3/31/2020	3,648	94	393	750	N/A
12/31/2019	3,613	115	439	766	N/A
9/30/2019	3,542	117	352	687	N/A
6/30/2019	3,471	119	264	607	N/A
3/31/2019	3,404	121	188	492	N/A
12/31/2018	3,336	123	113	377	N/A
9/30/2018	3,280	152	139	371	N/A
6/30/2018	3,224	180	165	364	N/A
3/31/2018	3,177	172	181	375	N/A
12/31/2017	3,131	163	197	385	N/A
9/30/2017	3,091	150	N/A	353	N/A
6/30/2017	3,052	137	N/A	320	N/A
3/31/2017	3,017	134	N/A	314	N/A
12/31/2016	2,981	131	N/A	307	N/A
9/30/2016	2,880	87	N/A	296	N/A
6/30/2016	2,779	42	N/A	284	N/A
3/31/2016	2,676	50	N/A	264	N/A
12/31/2015	2,573	59	N/A	245	N/A
9/30/2015	2,553	77	N/A	271	N/A
6/30/2015	2,533	95	N/A	297	N/A
3/31/2015	2,378	78	N/A	272	N/A
12/31/2014	2,222	61	N/A	247	N/A
9/30/2014	1,938	44	N/A	186	N/A
6/30/2014	1,654	27	N/A	126	N/A
3/31/2014	1,505	28	N/A	122	N/A
12/31/2013	1,356	29	N/A	119	N/A
9/30/2013	1,286	29	N/A	118	N/A
6/30/2013	1,216	29	N/A	118	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CLARI is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1%).

Earnings vs Market: CLARI is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: CLARI is expected to become profitable in the next 3 years.

Revenue vs Market: CLARI's revenue (5.4% per year) is forecast to grow slower than the French market (5.8% per year).

High Growth Revenue: CLARI's revenue (5.4% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: CLARI's Return on Equity is forecast to be low in 3 years time (1.3%).

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Clariane Future Growth

Future criteria checks 3/6

Key information

Recent future growth updates

Price target decreased by 12% to €3.83

Price target decreased by 11% to €4.01

Price target decreased by 22% to €6.73

Price target decreased by 11% to €10.44

Consensus EPS estimates fall by 82%

Consensus EPS estimates increase by 18%

Recent updates

Clariane (EPA:CLARI) Takes On Some Risk With Its Use Of Debt

Price target decreased by 12% to €3.83

Clariane Confirms Rumor of Disposal of HAD/SSIAD Business in France

Price target decreased by 11% to €4.01

Full year 2023 earnings released

Elevation Healthcare Properties managed by Elevation Advisors signed an agreement to acquire Berkley Care Group Ltd from Clariane SE (ENXTPA:CLARI) for £207 million.

Investor sentiment deteriorates as stock falls 22%

Investor sentiment deteriorates as stock falls 18%

Clariane SE to Report First Half, 2024 Results on Jul 30, 2024

Is It Too Late To Consider Buying Clariane SE (EPA:CLARI)?

Price target decreased by 22% to €6.73

Investor sentiment deteriorates as stock falls 17%

These 4 Measures Indicate That Clariane (EPA:CLARI) Is Using Debt Extensively

New major risk - Share price stability

Investor sentiment deteriorates as stock falls 31%

Clariane SE to Report Fiscal Year 2023 Results on Feb 28, 2024

Now 20% undervalued after recent price drop

Calculating The Fair Value Of Clariane SE (EPA:CLARI)

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 16%

Price target decreased by 11% to €10.44

Consensus EPS estimates fall by 82%

What Is Clariane SE's (EPA:CLARI) Share Price Doing?

First half 2023 earnings released

Clariane Announces Dividend for the Financial Year 2022, Payable on July 13, 2023

Clariane Announces Dividend for the Financial Year 2022, Payable on July 13, 2023

Upcoming dividend of €0.25 per share at 3.3% yield

Consensus EPS estimates increase by 18%

Now 21% undervalued after recent price drop

At €6.98, Is It Time To Put Korian (EPA:KORI) On Your Watch List?

These 4 Measures Indicate That Korian (EPA:KORI) Is Using Debt Extensively

Consensus EPS estimates increase by 20%

Price target decreased by 11% to €20.50

Investor sentiment deteriorates as stock falls 19%

Consensus EPS estimates fall by 50%, revenue upgraded

Price target decreased by 8.2% to €21.63

Full year 2022 earnings released

Price target decreased by 7.4% to €21.94

A Look At The Fair Value Of Korian (EPA:KORI)

Korian (ENXTPA:KORI) acquired Grupo 5 Acción y Gestión Social, S.A. from Corpfin Capital Asesores, S.A., SGEIC and others.

Should You Think About Buying Korian (EPA:KORI) Now?

Korian to Report First Half, 2023 Results on Jul 27, 2023

Does Korian (EPA:KORI) Have A Healthy Balance Sheet?

Consensus forecasts updated

Price target decreased to €24.69

Investor sentiment deteriorated over the past week

Is There Now An Opportunity In Korian (EPA:KORI)?

Is Korian (EPA:KORI) A Risky Investment?

First half 2022 earnings released

Korian Appoints Philippe Lévêque as Director and Chairman of the Ethics, Quality and CSR Committee

Upcoming dividend of €0.35 per share

Why Korian (EPA:KORI) Could Be Worth Watching

Investor sentiment deteriorated over the past week

Consensus forecasts updated

High number of new directors

Korian Proposes Dividend

Consensus forecasts updated

We Think Korian (EPA:KORI) Is Taking Some Risk With Its Debt

Full year 2021 earnings: Revenues in line with analyst expectations

Price target decreased to €32.60

Price target decreased to €34.30

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Korian (EPA:KORI) Has A Somewhat Strained Balance Sheet

Icade Santé SAS completed the acquisition of 2 nursing homes in Le Teilleul and Notre-Dame-de-Sanilhac from Korian (ENXTPA:KORI) for €13 million.

Korian (EPA:KORI) Seems To Be Using A Lot Of Debt

Korian Provides Sales Guidance for the Year 2022

Consensus forecasts updated

First half 2021 earnings released: EPS €0.31 (vs €0.13 in 1H 2020)